Jeito Capital has successfully closed its second fund, Jeito II, raising $1.2 billion and exceeding its initial target, in a move that underscores growing investor confidence in Europe’s biopharmaceutical sector. The milestone significantly expands the firm’s financial capacity, bringing its total assets under management to approximately €1.6 billion, nearly tripling since the launch of Jeito I in 2021.
The newly raised fund will continue Jeito’s strategy of investing in high-potential, clinical-stage biopharma companies, with a primary focus on Europe. The firm aims to back 15 to 20 companies developing innovative therapies for severe diseases with high unmet medical needs. With larger capital reserves, Jeito plans to increase its average investment per company to as much as €150 million, enabling portfolio firms to accelerate clinical development and unlock commercial opportunities more effectively.
Jeito II has already begun deploying funds across several high-demand therapeutic areas, including oncology, obesity, autoimmune and inflammatory diseases, neurology, reproductive health, and cardio-metabolic conditions. These sectors are expected to see strong growth, particularly as the pharmaceutical industry faces a looming patent cliff that could significantly impact revenues in the coming years.
Industry analysts estimate that the loss of exclusivity for major blockbuster drugs may lead to a decline of up to $400 billion in pharmaceutical revenues by 2033. As a result, large pharmaceutical companies are increasingly relying on smaller biopharma firms for innovation, with more than 70% of new drug developments now originating from such companies.
Jeito’s investment model is designed to address this shift by combining capital with strategic support. The firm provides continuous funding at key development stages while offering operational guidance through a multidisciplinary team of over 30 experts with experience across drug development, regulatory strategy, manufacturing, and commercialization. This integrated approach aims to help companies progress efficiently and expand beyond initial markets.
The firm has already demonstrated success with notable exits, including the acquisitions of EyeBio by Merck & Co. and Hi-Bio by Biogen, with combined deal values reaching several billion dollars and relatively short holding periods.
Jeito II has attracted a diverse group of global investors, including sovereign funds, institutional investors, and corporate partners across Europe, North America, and Asia. This broad support reflects strong confidence in both Jeito’s strategy and the long-term growth potential of the biopharma sector.
The successful fundraising also sends a positive signal for Europe’s life sciences ecosystem. While the region is recognized for its scientific excellence and innovation, many companies face challenges in accessing long-term growth capital. Jeito II is positioned to help bridge this gap, supporting the development of the next generation of global biopharma leaders.
Founder Dr. Rafaèle Tordjman described the fund closing as a major milestone, highlighting investor trust and the increasing role of European companies in driving global therapeutic innovation.